As of June 2026, neither compound is FDA-approved for any clinical use
This article is based on research published in Alternative Therapies in Health and Medicine (2021) by Edwin Lee and Blake Padgett
Nosemaglutide's weekly mechanism means timing doesn't alter its weight-loss efficacy over the long term
Kodama H, Yamaguchi R, Fukuda J, Kasai H, Tanaka T
These cells are uniquely responsive to fungal antigens and their metabolites, including mycotoxins such as gliotoxin, ochratoxin A, and aflatoxins 15
The literature focused on diabetes does not address this extensively, but it is a well-known clinical concern among patients using these medications for weight loss